Response to Imatinib in a Patient With Gastric Adenocarcinoma With <i>KIT</i> Q556_K558 In-Frame Deletion: A Case Report
Imatinib may be a useful targeted agent for patients with advanced gastric adenocarcinoma who have KIT mutations.
Authors
- Kiichiro Ninomiya (ORCID: https://orcid.org/0000-0002-2134-2865)
- Shinichi Toyooka (ORCID: https://orcid.org/0000-0002-7588-6745)
- Yoshinobu Maeda (ORCID: https://orcid.org/0000-0003-1634-5487)
- Go Makimoto (ORCID: https://orcid.org/0000-0002-0638-8435)
- Masahiro Tabata (ORCID: https://orcid.org/0000-0002-0008-2275)
- Kunio Okamoto (ORCID: https://orcid.org/0000-0001-7959-7089)
- Eiki Ichihara (ORCID: https://orcid.org/0000-0002-2966-106X)
- Shuta Tomida (ORCID: https://orcid.org/0000-0003-3786-936X)
- Natsuko Okita (ORCID: https://orcid.org/0000-0002-3990-5048)
- Daisuke Ennishi (ORCID: https://orcid.org/0000-0003-4788-2103)
- Yoshiyuki Ayada
- Satoko Nakamura (ORCID: https://orcid.org/0000-0003-4367-696X)
- Midori Ando
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
- Kagawa Prefectural Central Hospital (JP)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/po.24.00228
- Citations
- 1
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.46